In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...
Promoting interdisciplinary collaboration via molecular tumor boards and shared decision-making frameworks might improve the ...
AccuGenomics, Inc., a US-based leader in next-generation sequencing (NGS) quality standards, and 1Cell.Ai, a US-based precision oncology company specializing in single-cell and liquid biopsy ...
Results of a cross-sectional survey to explore determinants of health-promoting activities among Hispanic/Latino (H/L) patients (pts) with prostate cancer (PCa) on androgen deprivation therapy (ADT).
Wisconsin Physicians Service Insurance Corporation aligned its coverage determination with fellow contractor Palmetto GBA.
Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...
Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS® (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC Thermo ...
Rare and ultra-rare cancers represent an enormous unmet need that is not addressable with traditional approaches. Challenges to developing drugs to treat rare cancers are numerous: (1) extreme ...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...
Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback